Results 151 to 160 of about 21,820 (216)

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales. [PDF]

J Clin Microbiol
Bhatnagar AS, Harris H, Jacobs E, Bumpus-White P, Balbuena R, Stambaugh H, Crayton K, Haynie J, Quintero Ilutsik J, Longo C, Bergman Y, Singh S, Murray M, Sabour S, Robinson ML, Machado M-J, Simner PJ.   +16 more
europepmc   +1 more source

Ceftazidime-avibactam resistance evolution in <i>Pseudomonas aeruginosa</i> and implications for cross-resistance to other novel β-lactams. [PDF]

Antimicrob Agents Chemother
Dorazio AJ, Kline EG, Squires KM, Shah S, Van Tyne D, Wu JY, Pogue JM, Shields RK.   +7 more
europepmc   +1 more source

Ceftazidime-Avibactam as Early Empiric Therapy for Gram-Negative Nosocomial Infections: A Risk-Stratified Empiric Use Informed by National AMR Surveillance Data 2024. [PDF]

Antibiotics (Basel)
Subhi A, Subhi R, Sattar Y, Alshamsi S, Abdulrazzaq N, Chhabrani P.   +5 more
europepmc   +1 more source

Resistance development in KPC-producing <i>Klebsiella pneumoniae</i> under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy. [PDF]

Microbiol Spectr
Li F-H, Zheng M, Zhong G-M, He X-M, Hu M-Z, Kuang X, Wu J-J, Li C-M, Wang J-N, Zhou X-Y, Yu Y.   +10 more
europepmc   +1 more source

Erratum for Li et al., "Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy". [PDF]

Antimicrob Agents Chemother
Li C, Wang Y, Chen F, Huang L, Dong J, Fan W, Yue H, Ge Y.   +7 more
europepmc   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +1 more source

Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-Producing <i>Klebsiella pneumoniae</i> CNS Infection: A Case Report. [PDF]

Infect Drug Resist
Qi G, Cong W, Zhang M, Wang S, Bai Z, Li B, Chen H.   +6 more
europepmc   +1 more source

Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China. [PDF]

Front Cell Infect Microbiol
Qin X, Xiang T, Zhang X, Ma X, Zhao W, Yu Y, Zhao C, Gao L, Li L, Wang T, Pang C, Zhao X, Han R, Cao F, Su M, Lu J, Xu W, Yin S, Lu D, Yang X, Wang M.   +20 more
europepmc   +1 more source

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. [PDF]

Antimicrob Agents Chemother
Kunz Coyne AJ, Judd C, Lucas K, Al Musawa M, Van Helden S, Holger D, Althubyani A, Yost C, VanDorf S, Mynatt R, Kufel WD, Hayes J, Deri CR, Wrenn RH, Slaton CN, Morrisette T, Davis M, Cabanilla MG, Shald E, White BP, Sassine J, Truong J, Rosenberg J, Andrade J, Cerenzio J, Medvedeva N, Ha D, Eubank TA, Garey KW, Biagi M, Todd M, Kang-Birken SL, Rux C, Molina KC, Jankowski CA, Claeys KC, Venugopalan V, Veve MP, Orzol C, Eshaya M, Caniff KE, Bleick C, Rybak MJ.   +42 more
europepmc   +1 more source